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Abstract Coumarin embryopathy (CE) is a well-docu-
mented sequelae of prenatal exposure to vitamin K antag-
onists. We report on a female premature infant (25 weeks’
gestation) born to a mother who had received phenpro-
coumon during pregnancy following mechanical heart
valve replacement. The infant presented with impaired
coagulation, intraventricular and minor parenchymal cere-
bral haemorrhages and midface hypoplasia typical of CE.
In addition, there was hepatopathy with conjugated hyper-
bilirubinemia, elevated liver enzymes and repeated epi-
sodes of hypoglycemia upon attempts to discontinue
glucose supplementation, all lasting for 4 months. There
was corneal opacity with anterior segment dygenesis in the
left eye, and persistent pupillary membrane, cataract and
persistent hyperplastic primary vitreous in the right eye.
While liver disease is an uncommon but serious side effect
of vitamin K antagonists, this is the first report describing
neonatal hepatopathy as part of CE. In anticoagulation of
pregnant women with mechanical heart valves, vitamin K
antagonists should be used with utmost restraint.
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Introduction
Coumarin embryopathy (also known as fetal warfarin
syndrome or warfarin embryopathy) following prenatal
exposure to vitamin K antagonists was first reported in 1966
by DiSaia [7]. In a recent overview, Van Driel et al.
summarised 63 cases of CE (55 liveborn, five stillbirth and
three elective abortions) reported since 1959 [21]. About 6%
of all newborns exposed to coumarins throughout pregnancy
suffer from CE; of these, 80% develop skeletal anomalies
(e.g. midfacial hypoplasia, epiphyseal calcifications), 45%
have central nervous malformations (e.g. midline structure
defects) and 10% show signs of intracranial haemorrhage.
As coumarins readily cross the placenta and subsequently
affect fetal coagulation, there is a persistent risk for
intracranial bleedings until birth. The rate of spontaneous
abortion in women treated with coumarins throughout
pregnancy has been estimated to be as high as 30%.
Liver disease following treatment with vitamin K an-
tagonists is a rare but potentially serious complication
which normally resolves upon discontinuation of the med-
ication [5, 6, 11, 12, 16, 18, 19]. Here, we report on a very
preterm infant exposed to phenprocoumon in utero who
developed long-lasting hepatopathy in addition to signs of
classical CE.
Case report
The 28-year-old mother had been treated with phenpro-
coumon (Marcoumar; Roche Pharma, Switzerland) be-
cause of mechanical mitral valve replacement following
bacterial endocarditis. Upon becoming pregnant, she was
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advised to continue oral anticoagulation because of the
high risk situation for thrombo-embolic events. She re-
ceived 1.5–3 mg phenprocoumon per day, resulting in
International Normalised Ratios (INR) of 2.1–3.2. At
24 weeks‘ postmenstrual gestational age, she had vaginal
bleeding, and anticoagulation was changed to subcutane-
ous low-molecular-weight heparin (dalteparin, Fragmin;
Pfizer, Switzerland). Ultrasound showed minor cerebral
parenchymal bleeding and enlarged ventricles of the fetus.
The mother received steroids to induce fetal lung matura-
tion. At 25 4/7 weeks, a cesarean was performed because of
protracted fetal heart rate decelerations, and a female infant
was born with Apgar scores of 0/3/5, birthweight of 780 g
(P25–50), head circumference of 22.7 cm (P10) and a
length of 33 cm (P25–50). As phenprocoumon is charac-
terised by a long biological half-life time in vivo, the
infant’s INR was measured on the first day of life and
found to be 3.6. Lasting INR normalisation was achieved
after repeated administration of fresh frozen plasma during
the first 3 days of life. The infant had respiratory distress,
which was treated with surfactant replacement, mechanical
ventilation (35 days), continuous positive airway pressure
(20 days) and prolonged supplemental oxygen. A patent
ductus arteriosus closed following several rounds of ibu-
profen and indomethacin. She had four rounds of anti-
infectious medications (amoxicillin+clavulanic acid,
ceftazidime, amikacin and amphotericin B).
The infant showed midfacial hypoplasia with depressed
nasal bridge and a high-arched palate typical of CE (Fig. 1).
There were no epiphyseal calcific stipplings. Magnetic
resonance imaging showed small residual intraparenchy-
mal bleedings in the left frontal lobe, hypoplasia of the
cerebellum with a normal-sized fourth ventricle, an in-
fracerebellar arachnoid cyst, hypoplastic pontine structures
and normal images of other midline structures. Because of
neonatal seizures she was treated with phenobarbital from
the first day of life and additionally with phenytoin from
the 22nd until the 75th day of life.
Ophthalmologic examination showed bilateral abnor-
malities. In the left eye, there was a cloudy cornea with
deep vascularisation and a shallow anterior chamber with
pupillary deformation, suggestive of anterior segment
dysgenesis. In the right eye, there was a persistent pupillary
membrane, and the posterior pole was hard to visualise.
After resorption of the membrane, follow-up examinations
showed cataract and persistent hyperplastic primary
vitreous.
Soon after birth, the infant developed hepatomegaly and
persistent jaundice with conjugated hyperbilirubinemia
(peak: 112 μM at day 13 of life) and elevated liver enzymes
(peak ASAT: 151 U/l on day 96 of life; peak γGT: 256 U/l
on day 124 of life). Until 4 months of age, there was re-
current hypoglycemia unless the infant received glucose in
addition to regular meals. Thereafter, symptoms of hepatic
dysfunction receded. Investigations into possible infec-
tious, metabolic, anatomic and endocrinological reasons
for the liver dysfunction observed yielded negative results.
No liver biopsy was performed.
Discussion
Anticoagulation of pregnant women has been a matter of
debate between various experts [1, 2, 4, 8, 9, 15, 17, 20]
The European Society of Cardiology 2003 guidelines state
that continuation of vitamin K antagonist during the first
trimester of pregnancy is the safest therapeutic option for
the mother and that low-molecular-weight heparin should
not be recommended in patients with heart valve prostheses
during pregnancy. This recommendation is based on a
presumed mortality between 1 and 4% mainly due to valve
thrombosis while on heparin therapy [20]. In contrast, the
American College of Chest Physicians (ACCP) 2004
guidelines recommend dose-adjusted low-molecular-weight
heparin throughout pregnancy in women with prosthetic
heart valves [2]. The case reported here serves to document
the grave consequences for the fetus exposed to phenpro-
coumon in utero and, consequently, supports the ACCP-
2004 stance. In addition to CE-related midfacial hypoplasia
and sequelae of preterm birth, the baby girl had long-
lasting hepatopathy and is factually blind.
While eye anomalies, including congenital cataracts,
have been described as part of CE earlier, this is only the
second report [13] linking complex eye malformations to
intrauterine phenprocoumon exposure. The effect of cou-
marins on the developing eye and central nervous system
may be indirect due to (micro)haemorrhages, or direct,
through an interference with normal development during
organogenesis between 6–9 weeks of gestation. The most
recent investigations reveal that cartilage, bone and the
developing nervous system contain vitamin K-dependent
proteins [21]. The complications of coumarins seem to be
to dosage-dependent [22]. While the mother described
herein had received moderate doses, the protracted depres-
sion of the newborn infant’s INR 11 days after cessation of
phenprocoumon suggests that the fetus had been function-
ally overdosed.
Moreover, the premature born girl presented here ap-
pears to be the first case of phenprocoumon-related neo-
natal hepatitis. Hepatotoxicity is a rare but sometimes
serious adverse effect of coumarin medication [5, 6, 11, 12,
14, 16, 18, 19]. Whereas phenprocoumon seems to induce
Fig. 1 Photograph of face with
midfacial hypoplasia at age
3 months
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what appears to be a hepatitis-like alteration, warfarin and
acenocoumarol are thought to have more cholestatic effects
[6, 12]. The degree of liver damage ranges from asymp-
tomatically elevated liver enzymes to jaundice [6, 11, 19]
or rarely severe hepatic failure necessitating liver trans-
plantation [5, 16]. Symptoms of liver damage appear be-
tween 10 weeks and 8 months after initiation of the drug,
and the recovery of hepatic function occurs during the
period 1 to 5months after cessation [12, 18] This time course
is well in line with the clinical course of the baby presented
here. Clavulanic acid might have aggravated the liver dam-
age observed [3, 10], while phenytoin was administered only
after evidence of liver damage was apparent.
In conclusion, vitamin K antagonist-based anticoagula-
tion of pregnant women poses a considerable risk to the
fetus and as such warrants a search for a safer approach,
such as low-molecular-weight heparin.
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